This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Your September Biotech Back-to-School Calendar

BOSTON ( TheStreet) -- If you're like me, a dad with school-age kids, September is a real page turner in the calendar. Everyone gets a fresh start on January 1, but Labor Day serves the same purpose. The lazy days of summer are over, school is back in session and it's time to get back to real work.

The biotech sector hews close to an academic calendar and September marks the start of the busy, event-filled push into the end of the year. Here's a list of noteworthy and stock-moving September events:

The FDA has a full menu of approval decisions to make next month, including Keryx Pharmaceuticals (KERX - Get Report) (Zerenex) on Sept. 5, Orexigen Therapeutics (OREX) (Contrave) on Sept. 11, AstraZeneca (AZN) and Nektar Therapeutics (NKTR) (Movantik) on Sept. 16, Alimera Sciences (ALIM) (Iluvien) on Sept. 26 and Salix Pharmaceuticals (SLXP) (Relistor) on Sept. 29. 

Amarin (AMRN) is expected to hear from the FDA about the Vascepa Anchor SPA appeal in September.

NPS Pharmaceuticals (NPSP) brings the hypoparathryoidism drug Natpara in front of an FDA advisory panel on Sept. 12. 

Medicare officials are expected to propose a reimbursement price for Exact Sciences' (EXAS) Cologuard colon cancer screening test. 

The FDA has until October to render an approval decision on Gilead Sciences' (GILD - Get Report) single-pill combination therapy for hepatitis C and Merck's (MRK) anti PD-1 cancer immunotherapy pembrolizumab, but do not be surprised at all if approvals are announced early. 

A list of significant clinical trials with data announcements that could come in September:

Catalyst Pharmaceuticals (CPRX) (Firdapse phase III)
Alcobra (ADHD) (MG01CI phase III)
Discovery Labs (DSCO) (AeroSurf phase II)
Sunesis Pharma (SNSS - Get Report) (Qinprezo phase III)
Tetraphase Pharma (TTPH) (eravacycline phase III)
Xoma (XOMA) (gevokizumab phase III)
Lipocine (LPCN) (oral testosterone phase III)

Medical meetings:

ECTRIMS (multiple sclerosis) Sept. 10-14
EASD (diabetes0 Sept. 15-19
ESMO (oncology) Sept. 26-30

Healthcare investor conferences:

Baird (Sept. 3-4)
Citi (Sept. 3-4)
Rodman & Renshaw (Sept. 9-10)
Morgan Stanley (Sept. 8-10)
BioCentury (Sept. 26)

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AMRN $1.92 0.00%
CPRX $3.96 0.51%
GILD $111.71 0.44%
KERX $10.33 -3.10%
SNSS $2.44 0.41%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs